Payment overview · 2025
General Payments
$352.28
5 reported records · 4 companies
Healthcare provider profile · identity verified
David Lucious Oliver, DO
Allopathic & Osteopathic Physicians|Family Medicine · OCALA, FL · NPI 1164404455
Verified facts
What the public records show
CMS Open Payments records show David Lucious Oliver, DO received $352.28 in general payments during 2025 across 5 reported records.
Stryker Corporation accounted for 49.5% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 5 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Ozempic, Shingrix.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SHINGRIX as an associated drug or biological on 43515 records involving 26794 distinct recipient NPIs. Public Medicare Part D data also shows 128 claims for Shingrix by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 19 claims for Trelegy Ellipta by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 64 claims for Ozempic by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Stryker Corporation | Unresolved — no canonical attribution shown | $174.40 | 49.5% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $125.00 | 35.5% | 1 | 2025 |
| Philips North America LLC | Unresolved — no canonical attribution shown | $38.47 | 10.9% | 2 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $14.41 | 4.1% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $352.28 | 5 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| MAKO Normalized: mako |
Device | Stryker Corporation | $174.40 | 1 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $125.00 | 1 | 2025 |
Source payment records
|
|||||
| ECC Solutions Normalized: ecc solutions |
Device | Philips North America LLC | $19.94 | 1 | 2025 |
Source payment records
|
|||||
| Extended Holter Normalized: extended holter |
Device | Philips North America LLC | $18.53 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $14.41 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| Ozempic ozempic |
2025 | Ozempic | 2024 | 64 | exact normalized | Medicare Part D |
| SHINGRIX shingrix |
2025 | Shingrix | 2024 | 128 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | SHINGRIX open payments reported associated product |
CMS Open Payments — General Payments 43515 supporting records · 26794 recipient NPIs · example record 1190332452 |
Shingrix · 2024 Exact normalized brand match · 1 Part D row |
128 | 102 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
19 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
64 | 15 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Levothyroxine Sodium | Levothyroxine Sodium | 451 | 136 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 389 | 138 |
| Atorvastatin Calcium | Atorvastatin Calcium | 268 | 90 |
| Losartan Potassium | Losartan Potassium | 258 | 86 |
| Amlodipine Besylate | Amlodipine Besylate | 233 | 82 |
| Omeprazole | Omeprazole | 225 | 75 |
| Simvastatin | Simvastatin | 183 | 56 |
| Jardiance | Empagliflozin | 161 | 38 |
| Montelukast Sodium | Montelukast Sodium | 153 | 53 |
| Metoprolol Succinate | Metoprolol Succinate | 151 | 47 |
| Lisinopril | Lisinopril | 146 | 49 |
| Gabapentin | Gabapentin | 132 | 44 |
| Duloxetine Hcl | Duloxetine Hcl | 129 | 44 |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 128 | 102 |
| Valsartan | Valsartan | 114 | 35 |
| Pantoprazole Sodium | Pantoprazole Sodium | 110 | 42 |
| Hydrochlorothiazide | Hydrochlorothiazide | 109 | 42 |
| Allopurinol | Allopurinol | 100 | 34 |
| Carvedilol | Carvedilol | 99 | 28 |
| Clopidogrel | Clopidogrel Bisulfate | 99 | 33 |
| Metformin Hcl | Metformin Hcl | 98 | 34 |
| Tamsulosin Hcl | Tamsulosin Hcl | 98 | 32 |
| Glimepiride | Glimepiride | 94 | 33 |
| Trazodone Hcl | Trazodone Hcl | 90 | 38 |
| Metoprolol Tartrate | Metoprolol Tartrate | 82 | 28 |
| Potassium Chloride | Potassium Chloride | 81 | 31 |
| Famotidine | Famotidine | 79 | 26 |
| Escitalopram Oxalate | Escitalopram Oxalate | 74 | 30 |
| Furosemide | Furosemide | 74 | 28 |
| Fluticasone Propionate | Fluticasone Propionate | 72 | 32 |
| Celecoxib | Celecoxib | 69 | 29 |
| Alendronate Sodium | Alendronate Sodium | 65 | 31 |
| Bupropion Xl | Bupropion Hcl | 64 | 20 |
| Mounjaro | Tirzepatide | 64 | 17 |
| Ozempic | Semaglutide | 64 | 15 |
| Pravastatin Sodium | Pravastatin Sodium | 62 | 21 |
| Eliquis | Apixaban | 61 | 18 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 60 | 27 |
| Alprazolam | Alprazolam | 60 | 38 |
| Tramadol Hcl | Tramadol Hcl | 60 | 22 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 59 | 18 |
| Farxiga | Dapagliflozin Propanediol | 58 | 19 |
| Pioglitazone Hcl | Pioglitazone Hcl | 57 | 19 |
| Ezetimibe | Ezetimibe | 56 | 19 |
| Sertraline Hcl | Sertraline Hcl | 55 | 19 |
| Meloxicam | Meloxicam | 54 | 23 |
| Synthroid | Levothyroxine Sodium | 52 | 12 |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 51 | 14 |
| Spironolactone | Spironolactone | 44 | 17 |
| Xarelto | Rivaroxaban | 43 | 14 |
| Nebivolol Hcl | Nebivolol Hcl | 42 | 15 |
| Zolpidem Tartrate | Zolpidem Tartrate | 42 | 22 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 41 | 17 |
| Lovastatin | Lovastatin | 37 | 14 |
| Valacyclovir | Valacyclovir Hcl | 36 | 17 |
| Atenolol | Atenolol | 35 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 34 | 16 |
| Doxazosin Mesylate | Doxazosin Mesylate | 34 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 34 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 34 | 12 |
| Raloxifene Hcl | Raloxifene Hcl | 34 | 12 |
| Tizanidine Hcl | Tizanidine Hcl | 34 | 14 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 34 | 11 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 33 | suppressed |
| Glipizide | Glipizide | 32 | 11 |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 32 | suppressed |
| Boostrix Tdap | Diphth,pertuss(Acell),tet Vac | 31 | 26 |
| Pregabalin | Pregabalin | 31 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 30 | 11 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 30 | 11 |
| Jantoven | Warfarin Sodium | 29 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 29 | suppressed |
| Liothyronine Sodium | Liothyronine Sodium | 28 | 11 |
| Methocarbamol | Methocarbamol | 28 | 17 |
| Prednisone | Prednisone | 28 | 22 |
| Chlorthalidone | Chlorthalidone | 27 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 27 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 27 | 24 |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 26 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 25 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 24 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 24 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 24 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 24 | suppressed |
| Ibandronate Sodium | Ibandronate Sodium | 24 | 12 |
| Paroxetine Hcl | Paroxetine Hcl | 24 | suppressed |
| Telmisartan | Telmisartan | 24 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 23 | suppressed |
| Primidone | Primidone | 23 | suppressed |
| Clonazepam | Clonazepam | 22 | suppressed |
| Cyanocobalamin Injection | Cyanocobalamin (Vitamin B-12) | 21 | 13 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 21 | suppressed |
| Januvia | Sitagliptin Phosphate | 21 | suppressed |
| Mupirocin | Mupirocin | 21 | suppressed |
| Amoxicillin | Amoxicillin | 20 | 18 |
| Azithromycin | Azithromycin | 20 | 20 |
| Folic Acid | Folic Acid | 20 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 20 | suppressed |
| Repatha Sureclick | Evolocumab | 20 | suppressed |
| Estradiol | Estradiol | 19 | suppressed |
| Mirtazapine | Mirtazapine | 19 | suppressed |
| Ramipril | Ramipril | 19 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 19 | suppressed |
| Eszopiclone | Eszopiclone | 18 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 18 | 11 |
| Azelastine Hcl | Azelastine Hcl | 17 | suppressed |
| Clonidine | Clonidine | 17 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 17 | 11 |
| Amlodipine-Olmesartan | Amlodipine Bes/Olmesartan Med | 16 | suppressed |
| Dutasteride | Dutasteride | 16 | suppressed |
| Finasteride | Finasteride | 16 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 16 | suppressed |
| Irbesartan | Irbesartan | 16 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 16 | suppressed |
| Methylprednisolone | Methylprednisolone | 16 | 16 |
| Quetiapine Fumarate | Quetiapine Fumarate | 16 | suppressed |
| Risedronate Sodium | Risedronate Sodium | 16 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 16 | suppressed |
| Cephalexin | Cephalexin | 15 | 14 |
| Ipratropium Bromide | Ipratropium Bromide | 15 | suppressed |
| Verapamil Er | Verapamil Hcl | 15 | suppressed |
| Clotrimazole | Clotrimazole | 14 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 14 | suppressed |
| Fluconazole | Fluconazole | 14 | suppressed |
| Lorazepam | Lorazepam | 14 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 13 | 12 |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 13 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 13 | suppressed |
| Trulicity | Dulaglutide | 13 | suppressed |
| Ciclopirox | Ciclopirox | 12 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 12 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 12 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 12 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 12 | suppressed |
| Ulticare Pen Needle | Pen Needle, Diabetic | 12 | suppressed |
| Betamethasone Diprop Augmented | Betamethasone/Propylene Glyc | 11 | suppressed |
| Doxycycline Monohydrate | Doxycycline Monohydrate | 11 | 11 |
| Fenofibrate | Fenofibrate | 11 | suppressed |
| Premarin | Estrogens, Conjugated | 11 | suppressed |
| Prolia | Denosumab | 11 | suppressed |
| Temazepam | Temazepam | 11 | suppressed |
| Topiramate | Topiramate | 11 | suppressed |
| Torsemide | Torsemide | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $352.28 · 5 records | Stryker Corporation | ECC Solutions, Extended Holter, MAKO, Ozempic, SHINGRIX | 3 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Ozempic play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with GlaxoSmithKline, LLC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error